Anencephaly

Anencephaly is a severe neural tube defect. It occurs when the upper portion of the neural tube fails to close during early pregnancy, typically between days 23-26 of gestation. This results in the absence or severe underdevelopment of major portions of the brain, skull, and scalp. The condition specifically affects the formation of the cerebral hemispheres and the cranial vault that normally protects the brain.

Anencephaly is considered a fatal condition, with affected babies typically surviving only hours to days after birth. The brain stem may be present, which allows some basic functions to continue during pregnancy, but the absence of higher brain structures makes long-term survival impossible.

Anencephaly results from the failure of the neural tube to close properly during the first month of pregnancy. The exact cause is not fully understood, but it involves a combination of genetic and environmental factors. The neural tube, which eventually develops into the brain and spinal cord, normally closes by the 28th day after conception.

Risk factors include insufficient folic acid intake before and during early pregnancy, family history of neural tube defects, certain medications, maternal diabetes, and obesity. Most cases occur without any identifiable risk factors, and the majority are isolated occurrences rather than part of a genetic syndrome.

Anencephaly can often be detected during the first trimester, sometimes as early as 11-12 weeks of pregnancy during routine scanning. However, the condition is most commonly diagnosed during the detailed anomaly scan performed between 18-20 weeks of pregnancy. The characteristic absence of the cranial vault and brain tissue creates unmistakable ultrasound findings.

Detection rates are high because the anatomical changes are so distinctive. Additional tests such as maternal serum alpha-fetoprotein screening may also indicate increased risk, though ultrasound remains the primary diagnostic method for confirming anencephaly.

Anencephaly affects approximately 1 in 4,859 pregnancies according to CDC data, though the condition is more frequently seen in pregnancies than live births due to high rates of pregnancy loss. The prevalence varies geographically, with higher rates reported in certain regions such as Ireland and Wales historically, though rates have decreased significantly with folic acid supplementation programmes.

The condition shows a female predominance, affecting female fetuses approximately 3-4 times more often than males. The overall incidence has decreased substantially since the introduction of folic acid fortification and supplementation recommendations in many countries.

While not all cases can be prevented, the risk of anencephaly can be significantly reduced through adequate folic acid supplementation. Women planning pregnancy should take 400 micrograms of folic acid daily before conception and during the first 12 weeks of pregnancy. Those with higher risk factors may require higher doses of 5mg daily.

Other preventive measures include managing pre-existing diabetes, maintaining a healthy weight, avoiding certain medications that interfere with folate metabolism, and ensuring a balanced diet rich in folate. Countries with mandatory folic acid fortification of grain products have seen substantial reductions in neural tube defect rates.

The prognosis for anencephaly is unfortunately very poor, with the condition being incompatible with long-term survival. Babies born with anencephaly typically survive only hours to days after birth, though some may live for several days or weeks with supportive care. The absence of higher brain structures prevents normal neurological development and function.

Care focuses on comfort measures and supporting families during this difficult time. Some families choose palliative care approaches, whilst others may consider organ donation where appropriate. Medical teams work closely with families to provide compassionate support and respect their wishes regarding care decisions.

Screening for anencephaly involves several approaches, with ultrasound being the primary diagnostic method. The nuchal scan at 11-14 weeks may identify early signs, whilst the detailed anomaly scan at 18-20 weeks provides definitive diagnosis. Maternal serum screening can also detect elevated alpha-fetoprotein levels associated with neural tube defects.

Advanced screening options include certain forms of non-invasive prenatal testing that can assess risks for neural tube defects. However, ultrasound remains the gold standard for diagnosis, with the characteristic anatomical features being clearly visible on detailed scanning.

Anencephaly is typically not inherited as a single gene disorder, but there can be a familial predisposition to neural tube defects. The recurrence risk for couples who have had one pregnancy affected by anencephaly is slightly increased compared to the general population, which is higher than the general population risk but still means the vast majority of subsequent pregnancies will be unaffected.

Most cases occur sporadically without family history. However, certain rare genetic syndromes may include neural tube defects as features. Genetic counselling can help assess individual risks and discuss prevention strategies for future pregnancies, including higher dose folic acid supplementation.

Pregnancies affected by anencephaly may develop normally in early stages, with typical pregnancy symptoms and fetal movements often continuing. However, complications may arise later in pregnancy, including polyhydramnios (excess amniotic fluid) due to impaired fetal swallowing, and increased risks for the mother during delivery.

Some pregnancies may end in miscarriage naturally, whilst others continue to term or near-term. The management approach depends on various factors including the timing of diagnosis, family preferences, and medical considerations. Specialist obstetric care is typically recommended to monitor for complications and support decision-making.

Families facing an anencephaly diagnosis require comprehensive support including medical care, genetic counselling, and emotional support services. Many hospitals have specialist teams including fetal medicine consultants, genetic counsellors, and specialist midwives who can provide care and guidance throughout the pregnancy and beyond.

Support organisations and charities offer valuable resources, including connection with other families who have experienced similar diagnoses. Professional counselling services can help families process the diagnosis and make informed decisions about pregnancy management and future family planning.

The diagnosis of anencephaly is highly accurate when made during detailed scanning, as the anatomical features are very distinctive and unmistakable. The detection rate approaches 100% during detailed scanning, particularly during the second trimester anomaly scan when fetal structures are well-developed and clearly visible.

False positive diagnoses are extremely rare due to the characteristic appearance of the condition. However, it’s important that diagnosis is confirmed by specialists in fetal medicine, and families should feel comfortable seeking second opinions if desired to ensure complete confidence in the diagnosis.

Anencephaly can occasionally be associated with other structural abnormalities, though it often occurs as an isolated finding. When part of more complex conditions, it may be associated with spinal defects or other neural tube abnormalities. Comprehensive scanning is important to identify any additional anomalies that might affect management decisions.

In rare cases, anencephaly may be part of genetic syndromes, though the vast majority of cases are isolated neural tube defects. Detailed ultrasound examination and appropriate genetic evaluation can help determine whether other abnormalities are present and provide comprehensive information for families.

Following an anencephaly diagnosis, families face difficult decisions about pregnancy management. Options may include continuing the pregnancy with palliative care planning, or pregnancy termination if diagnosed before the legal limit. These decisions are deeply personal and should be made with comprehensive information and support from healthcare professionals.

Specialist counselling helps families understand all available options, including the practicalities and implications of each choice. Healthcare teams respect family decisions and provide appropriate ongoing care regardless of the path chosen, ensuring dignity and support throughout the process.

Having one pregnancy affected by anencephaly slightly increases the risk for future pregnancies, with a recurrence risk of approximately 3-5%. However, this still means that the vast majority of subsequent pregnancies will not be affected. Higher dose folic acid supplementation (5mg daily) is typically recommended for future pregnancies to reduce the risk further.

Preconception counselling and early prenatal screening can provide reassurance and early detection in subsequent pregnancies. Many families go on to have healthy pregnancies after experiencing anencephaly, with appropriate medical support and monitoring throughout the process.

Ongoing research into anencephaly focuses on understanding the genetic and environmental factors that contribute to neural tube defects, improving prevention strategies, and developing better support systems for affected families. Studies continue to investigate the complex interactions between genetic susceptibility and environmental factors such as nutrition and medication exposure.

Prevention research has been particularly successful, with folic acid supplementation and fortification programmes proving highly effective in reducing neural tube defect rates. Continued research aims to identify additional prevention strategies and improve outcomes for families affected by these conditions.